Background State-of-the art therapy for recurrent ovarian cancer (ROC) suitable for platinum-based re-treatment includes bevacizumab-containing combinations (eg, carboplatin/paclitaxel, carboplatin/gemcitabine) or the most active non-bevacizumab regimen: carboplatin/pegylated liposomal doxorubicin (PLD). This head-to-head trial compared a standard bevacizumab-containing regimen versus carboplatin/PLD combined with bevacizumab. Methods In this multicentre, open-label, randomised, phase 3 trial, eligible patients had histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma with first disease recurrence >6 months after first-line platinum-based chemotherapy, and were aged ≥18 years with Eastern Cooperative Oncology Group performance status 0-2. Patients were stratified by platinum-free interval, residual tumour, prior anti-angiogenic therapy, and study group language, and centrally randomised 1:1 using randomly permuted blocks of size two, four, or six to six intravenous cycles of carboplatin (AUC 4, day 1) plus gemcitabine (1000 mg/m 2 , days 1 and 8) every 3 weeks or six cycles of carboplatin (AUC 5, day 1) plus PLD (30 mg/m 2 , day 1) every 4 weeks, both given with bevacizumab (15 mg/kg every 3 weeks or 10 mg/kg every 2 weeks) until disease progression or toxicity. The primary endpoint was investigator-assessed progression-free survival (PFS). Efficacy data were analysed in the intention-to-treat population (all randomised patients). Safety was analysed in all patients who received at least one dose of study drug. This completed study is registered with ClinicalTrials.gov number NCT01837251.

The efficacy of oral co-amoxyclav, administered twice daily for up to 12 weeks either at the manufacturer's dose rate of 12.5 mg/kg or at 25.0 mg/kg, in curing the lesions of canine folliculitis, furunculosis and cellulitis was compared in a blind study. A total of 97 dogs entered the trial and 67 completed it. There was no significant difference in the rate of cure or the duration of therapy. The lesions of folliculitis were cured in 91.5 per cent of cases, in a mean period of 25.3 days. Furunculosis and cellulitis were cured respectively in 87.5 per cent and 60.0 per cent of the dogs, in mean periods of 37.6 and 44.7 days. The standard dose rate was very effective in folliculitis and furunculosis and there was no benefit in doubling the dose. Too few cases of cellulitis were treated to provide a reliable dose comparison.

A) E i n f u h r u n g Im Gegensatz zum Aryl-diazonium-kation entbehrt das Alkyldiazonium-ion der Mesomeriestabilisierung ; die Labilitat der Diazogruppe auI3ert sich in der raschen Abspaltung des Stickstoffmolekiils, wobei das zuruckbleibende Carbonium-ion mit dem Losungsmittel bzw . einem nucleophilen Agens weiterreagiert. Entzieht man aber etwa dem Methyl-diazonium-kation ein Proton, dann ermoglicht das freigelegte Elektronenpaar in I a der Diazogruppe die Entfaltung einer Mesomerie, die der des aromatischen Diazonium-ions entspricht. Eine solche Protonenabspaltung liegt tatsgchlich den bekannten Bildungswegen des Diazo-methans (I) aus Nitroso-acyl-methylaminenl), Nitroso-methylamino-isobutylmethyl-keton 2, u. a. Verbindungen zugrunde.Das 286; 1937, 1551.

Atopic dermatitis (AD) in dogs is among the most common skin diseases in small animal practice. It is an inflammatory disease based on a genetic predisposition to develop hypersensitivity against environmental and food allergens and typical clinical signs up exposure. Treatment sometimes can be difficult and associated with adverse effects. Previous studies evaluating cholecalciferol as treatment for human AD have shown promising results. With canine AD being a good animal model for its human counterpart, it was hypothesised that cholecalciferol might have beneficial clinical effects in dogs, too. In this randomised, placebo-controlled, double-blinded eight-week cross-over study, 23 client-owned dogs received either systemic cholecalciferol (n=16), a vitamin D receptor analogue (n=8) or placebo (n=13). Blood samples for ionised calcium were obtained regularly during the study, and Canine Atopic Dermatitis Extent and Severity Index and pruritus scores, blood levels of vitamin D metabolites, measurements of skin pH and transepidermal water loss were determined before and after. Pruritus and lesion scores decreased significantly in the cholecalciferol group versus placebo. No differences in water loss or skin pH were observed. An increase in serum 25-hydroxycholecalciferol strongly correlated with a reduction in pruritus. Systemic cholecalciferol may be a viable treatment option for canine AD.

Synthesis and Structure of CpAlCl2 Compounds with Sterically Demanding Substituents (Cp = Me5C5, EtMe4C5)[1] The compounds Cp*AlCl2 (3) (Cp* = Me5C5) and Cp′AlCl2 (4) (Cp′ = EtMe4C5) have been prepared by the reaction of Cp*SiMe3 (1) and Cp′SiMe3 (2) with AlCl3. The single‐crystal X‐ray structures of 3 and 4 are reported.